Our Mission
Our Mission
About OEP

Full-scale Multinational Company

Founded in 1982, Orient EuroPharma (OEP) became officially listed in the Taiwan Exchange in 2003. In the beginning, the Company was a prescription pharmaceutical distributor, but has now become a full-scale, multinational company. The core competencies of the Company not only include innovation, R&D, manufacturing, sales and clinical trials, but also a significant increase on operational efficiency through vertical integration, providing customers with more comprehensive services. In 2018, the Company has exceeded 930 employees worldwide, of which 40% are overseas personnel. The combined turnover has exceeded NT$5.5 billion.

The dedication of each member of the Company is evident. In an atmosphere that highly regards communication, we not only take data and proficiency seriously, but respect and value people. Our partners’ condition and opinion are of great importance. Through Integrity, united we achieve and be remarkable ─ This is the Company’s core value and is manifested in every detail we do to innovate and grow together.

Development of the Company – Starting from Consumer Needs

From the very beginning of its establishment, OEP has focused on meeting real needs of our daily lives. The Company is committed to providing products and services that are valuable and unique. Currently, OEP has three major business focuses on nutricare, prescription medicines, and anti-aging. We not only commits to developing our own brands, but also continues to seek cooperation opportunities with internationally renowned companies.

Since 2000, OEP has successively established overseas subsidiaries in Singapore, Malaysia, Hong Kong and the Philippines. In 2006, the Company established subsidiaries in Mainland China, and is steadily cultivating the Asia-Pacific market and gradually reaching the goal of becoming a benchmark enterprise in the Asia Pacific.

Mission and Vision
OEP strives to fulfill the mission of “enhancing health and beauty” and the pursuit of corporate growth. Built on understanding the real needs of people and achieving business sustainability, the Company continuously offers valuable products and services to our customers.
Milestones
1982

Founded Orient EuroPharma Co., Ltd and marketed prescription medicine.

1989

Imported infant goat formula from New Zealand, and the first private brand “Karihome” was born in Taiwan.

1999

Invested in the GMP pharmaceutical plant and medical R&D.

OEP began deploying its overseas channels in Singapore, Malaysia, and Hong Kong, entering the Southeast Asian markets with prescription medicine.

2002

Purchased farms in New Zealand, becoming the first Taiwan goat milk supplier with approved membership in the New Zealand Dairy Board.

Established new offices in Philippines, further expanding the Company’s Southeast Asian territory.

Established the medical cosmetics department and entered the skincare market.

2003

Officially listed for OTC trading (stock code: 4120)

2004

“Karihome” marketed in Hong Kong, which was the time that our milk powder business entering overseas market.

2005

“Karihome” series were marketed in Malaysia.

2007   “Karihome” series were marketed in Singapore.
2008

Established subsidiary company, Orient PHARMA Co., Ltd.

“Karihome” series marketed in China, which was the first product of OEP entering China market.

2010

Established offices in Vietnam, enhancing Southeast Asian channels.

2011

Orient PHARMA Co., Ltd awarded Taiwan’s Food and Drug Administration PIC/S GMP certification.

2012

OEP established a professional dermo cosmetics sales team in the Philippines, setting up its dermo cosmetic business in an overseas market for the first time.

Orient PHARMA Co., Ltd officially listed for OTC trading (stock code: 4166)

Orient PHARMA Co., Ltd awarded Japan’s official foreign pharmaceutical manufacturer certification.

2013

Orient PHARMA Co., Ltd awarded U.S. Food and Drug Administration Manufacturing Plant Inspection certification.

2014

Signed agreement with Japan’s NanoCarrier Co., Ltd. to develop new cancer drug and construct a new plant.

First ANDA approved by US FDA, officially entered US market.

2016

The first anti-hyperlipidemia drug developed by OEP was officially launched in Taiwan.

OEP entered a cooperative agreement with Second Sight, acquiring exclusive distribution rights for the Argus II Retinal Prosthesis System in Taiwan and entering the field of ophthalmology.

OEP signed a cooperative agreement with American company TissueTech, acquiring exclusive rights for the next series of ophthalmologic tissue products in Asia Pacific and stepping into the field of regenerative medicine.

2017 Vietnam office was restructured into a subsidiary of OEP.

A subsidiary was established in Indonesia, expanding the Southeast Asian market.

2018 Construction of the production facilities for subsidiary OP NanoPharma Co., Ltd was completed, marking the beginning of use of nano-particle micellar delivery technology to produce anti-cancer injectable solutions and powders.
Honor
2007

Orient EuroPharma Co., Ltd achieved class A+ for the 4th annual Information Enclosure Evaluation.

2009

Karihome Goat Milk of Orient Pharma led for years regarding to TNS model market survey.

2010

Orient EuroPharma Co., Ltd achieved class A+ for the 7th annual Information Enclosure Evaluation.

2011

Orient EuroPharma Co., Ltd achieved class A+ for the 8th annual Information Enclosure Evaluation.

Honored with the 1st Gre Tai Securities Market Golden laurel Award for excellent and sustainable enterprise.

2012

Ranked 600th among the top thousand large enterprises named by the CommonWealth Magazine.

2013

Ranked 549th among the top thousand large enterprises named by the CommonWealth Magazine.

Orient EuroPharma Co., Ltd achieved class A+ for the 10th annual Information Enclosure Evaluation.

Orient EuroPharma Co., Ltd named as one of the top three benchmark biotechnology by the Institute for Biotechnology and Medicine Industry.

2014

Ranked 538th among the top thousand large enterprises named by the CommonWealth Magazine.

Orient EuroPharma Co., Ltd achieved class A+ for the 11th annual Information Enclosure Evaluation.

2015

Ranked 526th among the top thousand large enterprises named by the CommonWealth Magazine.

Orient EuroPharma Co., Ltd was named again as one of Benchmark Pharmaceutical Company (Bio Taiwan Highlight) By IBMI (Institute for Biotechnology and Medicine Industry).

2016

Ranked 508th among the top thousand large enterprises named by the CommonWealth Magazine.

2017

Ranked 484th among the top thousand large enterprises named by the CommonWealth Magazine.

2018  The subsidiary in Singapore was ranked 88th in the 2015 and 2016 Top 100 Taiwanese Business in ASEAN for revenue and profit growth.